Epilepsy News and Research

Latest Epilepsy News and Research

The neuroscience of musical chills

Scientists have found that the pleasurable experience of listening to music releases dopamine, a neurotransmitter in the brain important for more tangible pleasures associated with rewards such as food, drugs and sex. The new study from The Montreal Neurological Institute and Hospital - The Neuro at McGill University also reveals that even the anticipation of pleasurable music induces dopamine release [as is the case with food, drug, and sex cues].

13 Jan 2011

Emotional stress can affect motor coordination and other cerebellum-dependent cognitive functions: Study

Research conducted by Iaroslav Savtchouk, a graduate student, and S. June Liu, PhD, Associate Professor of Cell Biology and Anatomy at LSU Health Sciences Center New Orleans, has shown that a single exposure to acute stress affected information processing in the cerebellum - the area of the brain responsible for motor control and movement coordination and also involved in learning and memory formation.

13 Jan 2011

UCLA imaging system could help reveal 'miscommunications' in autism, schizophrenia

Some disorders of the brain are obvious - the massive death of brain cells after a stroke, the explosion in the growth of cells that marks a tumor. Other disorders, such as autism, schizophrenia and mental retardation show no physical signs of damage and are believed to be caused by problems in how brain cells communicate with one another.

13 Jan 2011

Two signaling molecules communicate across nerve cells to regulate electrical, chemical activity: Study

In the Old West, camps sent smoke signals across distances to share key developments or strategy. Likewise, two important signaling molecules communicate across nerve cells to regulate electrical and chemical activity, neuroscientists from the UT Health Science Center San Antonio reported today.

10 Jan 2011

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.

7 Jan 2011

Researchers say women with multiple sclerosis have more HLA genes than men

Women who have multiple sclerosis (MS) are more likely to have a gene associated with multiple sclerosis than men with the disease and it is this gene region where environment interacts with the genetics, according to a study published in the January 5, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology.

6 Jan 2011

Maternal depression adversely affects quality of life in children with epilepsy

A study by Canadian researchers examined the prevalence of maternal depression and its impact on children newly diagnosed with epilepsy. Prevalence of depression in mothers ranged from 30%-38% within the first 24 months following a child’s epilepsy diagnosis. The mother’s depressive symptoms negatively impacted the child’s health-related quality of life, but the effects were moderated by the amount of family resources and mediated by how well the family functions and the extent of family demands. Details of this novel study appear online in Epilepsia, a journal published by Wiley-Blackwell on behalf of the International League Against Epilepsy.

5 Jan 2011

Child's epilepsy diagnosis impacts mother's mental health and family environment

5 Jan 2011

18F-FDG PET scans help evaluate cognitive dysfunction of pediatric fever-induced epilepsy

Sudden, catastrophic childhood epilepsy is a parent's worst nightmare, especially in the case of fever-induced refractory epileptic encephalopathy in school-age children (FIRES). While not much is known about the condition, new research published in the January issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans can offer an evaluation of cognitive dysfunction of FIRES, its evolution and further prognosis.

4 Jan 2011

Epilepsy more common than earlier thought: Study

Epilepsy prevalence and incidence is greater than earlier thought in the United States. The latest study shows that one in every 26 people in the United States will develop epilepsy at some point in their life. Experts believe this new revelation calls for more attention and funding for the disease.

29 Dec 2010

Natus Medical ships ALGO hearing screeners to New South Wales

Natus Medical Incorporated today announced that it was awarded, and has shipped, a $1.3 million order for its ALGO hearing screeners from New South Wales, Australia's most populous state.

29 Dec 2010

Epilepsy not getting the public attention and research funding it deserves

Epilepsy, a common and serious neurologic disorder that affects millions of people, is not getting the public attention and funding for research it deserves, according to an editorial on a study published in the January 4, 2011, print issue of Neurology®, the medical journal of the American Academy of Neurology.

28 Dec 2010

Fried fish consumption may increase risk of stroke

People living in the "stroke belt" states eat more fried fish than people living in the rest of the country, which may contribute to the high rate of death from stroke in those states, according to a study published in the December 22, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

23 Dec 2010

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Vertex Pharmaceuticals Incorporated today announced a modification of its Phase 2 clinical trial evaluating 12-week, response-guided regimens of its lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.

22 Dec 2010

$Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy$

Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy

Cyberonics, Inc. announced today that the VNS Therapy System, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, was featured in 22 poster presentations and in the Plenary II session on neurostimulation at the annual American Epilepsy Society Meeting that took place recently in San Antonio, Texas.

22 Dec 2010

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

Anavex Life Sciences Corp. announced today that it has filed the regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Dec 2010

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.

20 Dec 2010

Proteins that unlock the mystery of over 100 brain diseases

An Anglo-American team of researchers have made a medical breakthrough after identifying a large collection of nerve proteins that are involved in around 130 brain diseases including Alzheimer’s and autism.

20 Dec 2010

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Icagen, Inc. today provided an update on its sodium channel program for pain and related disorders, which is being conducted in collaboration with Pfizer. As previously reported, the companies recently selected a candidate compound to advance into further clinical studies. Dosing of this candidate compound has now been initiated in a Phase I study in healthy volunteers.

20 Dec 2010

Natus Medical anticipates revenue of $247M to $250M for full year 2011

Natus Medical Incorporated today announced its financial guidance for the first quarter and full year 2011.

20 Dec 2010

Epilepsy News and Research

Latest Epilepsy News and Research

The neuroscience of musical chills

Emotional stress can affect motor coordination and other cerebellum-dependent cognitive functions: Study

UCLA imaging system could help reveal 'miscommunications' in autism, schizophrenia

Two signaling molecules communicate across nerve cells to regulate electrical, chemical activity: Study

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

Researchers say women with multiple sclerosis have more HLA genes than men

Maternal depression adversely affects quality of life in children with epilepsy

Child's epilepsy diagnosis impacts mother's mental health and family environment

18F-FDG PET scans help evaluate cognitive dysfunction of pediatric fever-induced epilepsy

Epilepsy more common than earlier thought: Study

Natus Medical ships ALGO hearing screeners to New South Wales

Epilepsy not getting the public attention and research funding it deserves

Fried fish consumption may increase risk of stroke

Vertex announces modification of telaprevir and VX-222 combination Phase 2 trial for treatment of HCV

Emory University study reaffirms benefits of VNS Therapy System for refractory epilepsy

Anavex files regulatory submission in Germany for ANAVEX 2-73 Phase I trial in Alzheimer's disease

VistaGen reports successful completion of AV-101 Phase 1 safety study for neuropathic pain

Proteins that unlock the mystery of over 100 brain diseases

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Natus Medical anticipates revenue of $247M to $250M for full year 2011

Everything you need to know about epilepsy eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Epilepsy News and Research

Latest Epilepsy News and Research

Everything you need to know about epilepsy eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in